When is crossover desirable in cancer drug trials and when is it problematic?

A. Haslam, V. Prasad

Research output: Contribution to journalEditorial

2 Citations (Scopus)
Original languageEnglish
Number of pages1
JournalAnnals of Oncology
Volume29
Issue number5
DOIs
StatePublished - 1 May 2018
Externally publishedYes

Fingerprint

Pharmaceutical Preparations
Neoplasms

Cite this

@article{f488465f996c48939658f0b346de93fb,
title = "When is crossover desirable in cancer drug trials and when is it problematic?",
author = "A. Haslam and V. Prasad",
year = "2018",
month = "5",
day = "1",
doi = "10.1093/annonc/mdy116",
language = "English",
volume = "29",
journal = "Annals of oncology : official journal of the European Society for Medical Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "5",

}

When is crossover desirable in cancer drug trials and when is it problematic? / Haslam, A.; Prasad, V.

In: Annals of Oncology, Vol. 29, No. 5, 01.05.2018.

Research output: Contribution to journalEditorial

TY - JOUR

T1 - When is crossover desirable in cancer drug trials and when is it problematic?

AU - Haslam, A.

AU - Prasad, V.

PY - 2018/5/1

Y1 - 2018/5/1

UR - http://www.scopus.com/inward/record.url?scp=85047609411&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdy116

DO - 10.1093/annonc/mdy116

M3 - Editorial

C2 - 29648572

AN - SCOPUS:85047609411

VL - 29

JO - Annals of oncology : official journal of the European Society for Medical Oncology

JF - Annals of oncology : official journal of the European Society for Medical Oncology

SN - 0923-7534

IS - 5

ER -